Quarterly ResultMay 8, 2026, 07:07 AM
Boundless Bio Q1 Net Loss $13.6M; KOMODO-1 Enrollment Ongoing
AI Summary
Boundless Bio reported its first quarter 2026 financial results, showing a reduced net loss of $13.6 million compared to $15.8 million in the prior year. The company maintained a strong cash position of $92.8 million, providing a runway into the second half of 2028. Additionally, enrollment is progressing in the KOMODO-1 clinical trial for BBI-940, with initial proof-of-concept data anticipated within the existing cash runway, supported by positive preclinical data presented at AACR 2026.
Key Highlights
- Cash, cash equivalents, and short-term investments totaled $92.8 million as of March 31, 2026.
- Company expects cash to fund operations into the second half of 2028.
- Net loss for Q1 2026 was $13.6 million, an improvement from $15.8 million in Q1 2025.
- Net loss per share was $(0.60) for Q1 2026, compared to $(0.71) in Q1 2025.
- Research and Development expenses decreased to $9.7 million in Q1 2026 from $12.1 million in Q1 2025.
- Enrollment is ongoing in the KOMODO-1 first-in-human clinical trial for BBI-940.
- Initial safety and efficacy clinical proof-of-concept data for KOMODO-1 expected within cash runway.
- Preclinical data at AACR 2026 showed BBI-940's anti-tumor activity and tumor regression.